IQVIA Holdings stock holds above $260 as Q2 2026 beat and raised guidance support the outlook
Published on 08/28/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IQVIA Holdings Inc. (US46266C1053) stock is trading in the low-$260s on August 28, 2026, supported by a solid second-quarter 2026 earnings beat and an uplift to full-year guidance that underline growing demand for its data-driven healthcare services.
As of August 28, 2026, a real-time market snapshot shows IQVIA shares changing hands at $259.70 during the New York Stock Exchange session, compared with a previous closing price of $262.38, reflecting a modest intraday decline of 1.10% after a recent run-up that has taken the stock above the $260 mark.
Recent quoting data also indicate that IQVIA opened the latest completed trading day close to $255 and closed at $261.51 on August 26, 2026, highlighting that the current price region is near the top of the recent range and that investors are keeping the stock well above mid-August levels as they digest the company’s latest results and guidance.
Q2 2026 earnings beat with double-digit EPS growth
IQVIA’s second-quarter 2026 results mark a meaningful step-up in profitability, with adjusted earnings per share reported at $3.15 for the period, an increase of 12.1% compared with the same quarter a year earlier and ahead of the consensus estimate of $3.02 by 4.3% as summarized in a recent earnings review sourced from a market analysis portal.
On the top line, second-quarter 2026 revenue reached $4.36 billion, rising 8.7% year over year and coming in above the $4.29 billion consensus figure, illustrating that IQVIA is delivering both growth and a small but tangible beat versus expectations across its diversified portfolio of clinical research and commercial services.
Within that total, the Research and Development Solutions segment generated second-quarter 2026 revenues of $2.58 billion, up 8.8% on a reported basis compared with the prior-year quarter, while Commercial Solutions contributed $1.79 billion, an 8.6% year-on-year increase, showing that demand is broad-based across both trial execution and data-driven sales and marketing support.
IQVIA also reported record net new bookings for its R&D Solutions activities in the second quarter of 2026, with $3.15 billion of newly signed work representing a 19% year-over-year increase and producing a book-to-bill ratio of 1.22, underscoring that future revenue visibility is strengthening as the company wins more long-term contracts than it delivers in the period.
On profitability, adjusted EBITDA climbed to $994 million in the second quarter of 2026, up 9.2% from the prior-year period, translating into an adjusted EBITDA margin of 22.8%, which was modestly above the level recorded a year earlier as earnings growth outpaced revenue growth and cost discipline offset ongoing investment spending.
Adjusted net income followed a similar trajectory, increasing to $527 million in the second quarter of 2026 compared with $486 million in the prior-year quarter, demonstrating that the uplift in operating performance is flowing through to the bottom line even after accounting for interest and other non-operating items.
While GAAP diluted earnings per share stood at $1.53 in the second quarter of 2026 compared with $1.54 a year earlier, the underlying cash generation improved, with operating cash flow for the quarter rising 26% year over year to $558 million and free cash flow growing 23.3% to $360 million after $198 million of capital expenditure on property, equipment and software.
For the first half of 2026, IQVIA’s operating cash flow reached $1.18 billion and free cash flow totaled $851 million, figures that underline the company’s ability to convert earnings into cash and support both investment and shareholder returns.
The company also returned capital during the period by repurchasing $398 million of common stock in the second quarter of 2026, bringing total share buybacks in the first half of 2026 to $950 million, which, combined with earnings growth, helps support per-share metrics and may underpin the stock’s resilience above the $260 level.
Raised 2026 guidance and supportive consensus
In conjunction with the second-quarter 2026 earnings release, IQVIA raised its guidance for full-year 2026, signaling increased confidence in its ability to deliver stronger growth and profitability than previously expected, according to a same-day strategic commentary that highlights the impact of the beat-and-raise on the company’s investment narrative.
Consensus estimates compiled by a financial data platform now point to 2026 adjusted EPS of 13.64, within a published range of forecasts between 13.09 and 14.66, suggesting that the market expects continued double-digit earnings growth from the second-quarter run rate and leaving room for IQVIA to either meet or modestly exceed those levels if execution remains strong.
On the revenue side, current consensus for full-year 2026 stands at $17.91 billion, within a range of $17.72 billion to $18.23 billion, which, when compared with the second-quarter 2026 revenue of $4.36 billion, implies that analysts expect a sustained pace of mid- to high-single-digit growth across the remaining quarters of the year.
One forward-looking narrative cited in recent coverage projects that IQVIA could reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, framing the company as a long-term compounder in data-driven healthcare, although such medium-term projections are inherently subject to execution risks, regulatory developments and the broader funding environment for life sciences.
In the shorter term, a separate institutional ownership update notes that one large financial group recently reported holding 84,902 IQVIA shares, and that the stock carried an average rating of “Moderate Buy” with a consensus target price of $241.88 at the time of that filing, implying that the current trading level slightly above $260 already stands above that average target and reflects investors’ willingness to pay a premium for IQVIA’s growth profile.
Market data from the same consensus overview show that IQVIA closed at $261.51 on August 26, 2026, up 0.81% on the day, reinforcing the message that the shares have been trending higher in recent sessions and that the strong second-quarter 2026 results and raised outlook are translating into steady support in the market.
For investors, the combination of a double-digit EPS increase, mid- to high-single-digit revenue growth and expanding bookings in Q2 2026 suggests that IQVIA is successfully leveraging its scale in clinical research and analytics, which may help buffer the business against cyclical swings and support continued cash generation for buybacks and debt reduction.
Data-driven clinical and commercial solutions
IQVIA’s core business revolves around providing data-rich solutions to pharmaceutical companies, biotech firms and healthcare providers, combining contract research services with analytics and technology platforms that help clients design, run and optimize clinical trials and commercial strategies.
In the second quarter of 2026, the record $3.15 billion of net new bookings in R&D Solutions, coupled with the 1.22 book-to-bill ratio, illustrate how IQVIA’s clinical research arm is winning new studies at a rate that exceeds revenue recognition, reinforcing a multi-year backlog that provides visibility into future workloads.
Commercial Solutions revenue of $1.79 billion in Q2 2026 shows that the company’s offerings around data-driven sales force effectiveness, real-world evidence and marketing analytics remain in demand as life sciences companies seek to tailor their outreach and measure outcomes more precisely.
The adjusted EBITDA margin of 22.8% in Q2 2026 demonstrates that IQVIA can balance growth with profitability while continuing to invest in technology and data assets, and the improvement over the prior-year margin suggests that operating leverage is starting to emerge as volumes grow.
Free cash flow of $360 million in the second quarter of 2026, combined with $851 million in the first half, gives IQVIA flexibility to fund internal projects, consider bolt-on acquisitions and continue share repurchases without compromising its ability to manage its leveraged balance sheet.
IQVIA’s long-term narrative pointing to potential revenue of $20.4 billion and earnings of $2.0 billion by 2029 underscores the scale of the opportunity it sees in global clinical development and data analytics, but the execution path will depend heavily on maintaining booking growth, managing regulatory complexity and integrating new digital tools into its workflow.
Representative offering: technology-enabled clinical trial platform
A representative example of IQVIA’s product portfolio is its technology-enabled clinical trial platform, which integrates patient recruitment, data capture and analytics into a single environment designed to streamline study execution.
This type of platform leverages IQVIA’s extensive data assets and software capabilities to help sponsors identify eligible patients more efficiently, monitor safety and efficacy signals in near real time, and adapt trial protocols in response to emerging insights while staying within regulatory frameworks.
For healthcare clients, such solutions aim to reduce the time and cost required to bring new therapies to market by minimizing delays in recruitment, improving data quality and enabling more agile decision-making, which in turn can translate into better returns on R&D spending.
IQVIA stock price context
IQVIA shares trade on the New York Stock Exchange under the ticker IQV, with recent market data showing an intraday quote of $259.70 on August 28, 2026, compared with a prior close of $262.38, following a completed session close at $261.51 on August 26, 2026.
Against the backdrop of a strong second quarter of 2026 and raised full-year guidance, the current price region slightly above $260 sits above published consensus target levels, indicating that investors have bid the stock up in anticipation of sustained earnings growth and continued demand for IQVIA’s data-driven healthcare solutions.
Fact box
Company: IQVIA Holdings Inc.
ISIN: US46266C1053
Ticker: IQV
Exchange: NYSE
Price (as of August 28, 2026, 11:24 a.m. ET): $259.70 USD
Market cap: Data not specified here
Sector / Industry: Healthcare - Life sciences tools and services
Index membership: S&P 500
